Outcomes on safety and efficacy of left atrial appendage occlusion in end stage renal disease patients undergoing dialysis
暂无分享,去创建一个
F. Pieruzzi | E. Piccaluga | M. Valsecchi | F. Viazzi | M. Breschi | P. Rebora | S. Genovesi | A. Gaspardone | L. Porcu | S. Bertoli | M. Gallieni | P. Mazzone | F. Ettori | J. Oreglia | G. Rovaris | G. Casu | G. Molon | M. Gaggiotti | R. Palumbo | G. D'Angelo | A. Sagone | P. Merella | A. Montoli | G. Slaviero | Gina Contaldo | M. Buskermolen | F. Galli | G. D’Angelo
[1] S. Kische,et al. Initial and long-term antithrombotic therapy after left atrial appendage closure with the WATCHMAN , 2020 .
[2] A. Davenport,et al. Coronary artery disease in dialysis patients: evidence synthesis, controversies and proposed management strategies , 2020, Journal of Nephrology.
[3] S. Kische,et al. Initial and long-term antithrombotic therapy after left atrial appendage closure with the WATCHMAN. , 2020, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[4] M. Fusaro,et al. Systematic DOACs oral anticoagulation in patients with atrial fibrillation and chronic kidney disease: the nephrologist’s perspective , 2020, Journal of Nephrology.
[5] S. Bangalore,et al. Oral Anticoagulation for Patients With Atrial Fibrillation on Long-Term Hemodialysis. , 2020, Journal of the American College of Cardiology.
[6] A. Mügge,et al. Risk stratification in patients undergoing interventional left atrial appendage occlusion—Prognostic impact of EuroSCORE II , 2020, Clinical cardiology.
[7] M. Kelm,et al. Kidney function stratified outcomes of percutaneous left atrial appendage occlusion in patients with atrial fibrillation and high bleeding risk , 2020, Acta cardiologica.
[8] A. Regueiro,et al. Percutaneous Left Atrial Appendage Closure, A Safe Alternative To Anticoagulation For Patients With Non-Valvular Atrial Fibrillation And End-Stage Renal Disease On Hemodialysis: A Single Center Experience. , 2019, Artificial organs.
[9] A. Camm,et al. EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion - an update. , 2019, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[10] R. Akehurst,et al. Cost‐Effectiveness of Left Atrial Appendage Closure for Stroke Reduction in Atrial Fibrillation: Analysis of Pooled, 5‐Year, Long‐Term Data , 2019, Journal of the American Heart Association.
[11] P. Berne,et al. Left Atrial Appendage Occlusion in High Bleeding Risk Patients , 2019, Journal of interventional cardiology.
[12] J. MacRae,et al. Anticoagulation in CKD and ESRD , 2019, Journal of Nephrology.
[13] I. Cruz-González,et al. Left Atrial Appendage Occlusion in Hemodialysis Patients: Initial Experience. , 2019, Revista espanola de cardiologia.
[14] P. Berne,et al. Nonvalvular atrial fibrillation in high-hemorrhagic-risk patients: state of the art of percutaneous left atrial appendage occlusion , 2019, Journal of cardiovascular medicine.
[15] P. Noseworthy,et al. Outcomes Associated With Apixaban Use in Patients With End-Stage Kidney Disease and Atrial Fibrillation in the United States , 2018, Circulation.
[16] K. Chun,et al. Antithrombotic strategies after interventional left atrial appendage closure: an update , 2018, Expert review of cardiovascular therapy.
[17] J. Camm,et al. Left atrial appendage occlusion with the AMPLATZER Amulet device: one-year follow-up from the prospective global Amulet observational registry. , 2018, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[18] F. Pieruzzi,et al. Implant success and safety of left atrial appendage occlusion in end stage renal disease patients: Peri-procedural outcomes from an Italian dialysis population. , 2018, International journal of cardiology.
[19] A. Camm,et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. , 2018, European heart journal.
[20] Jiangtao Yu,et al. Impact of chronic kidney disease on Watchman implantation: experience with 300 consecutive left atrial appendage closures at a single center , 2018, Heart and Vessels.
[21] S. Kische,et al. Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-Year follow-up outcome data of the EWOLUTION trial. , 2017, Heart rhythm.
[22] A. Santoro,et al. Effect of oral anticoagulant therapy on mortality in end-stage renal disease patients with atrial fibrillation: a prospective study , 2017, Journal of Nephrology.
[23] P. Kirchhof,et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.
[24] Bingjian Wang,et al. Efficacy and Safety of Percutaneous Left Atrial Appendage Occlusion for Stroke Prevention in Nonvalvular Atrial Fibrillation: A Meta-analysis of Contemporary Studies. , 2016, Heart, lung & circulation.
[25] P. Kirchhof,et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[26] D. Brancaccio,et al. Patients' Characteristics Affect the Survival Benefit of Warfarin Treatment for Hemodialysis Patients with Atrial Fibrillation. A Historical Cohort Study , 2016, American Journal of Nephrology.
[27] P. Schulman,et al. Stroke, Major Bleeding, and Mortality Outcomes in Warfarin Users With Atrial Fibrillation and Chronic Kidney Disease: A Meta-Analysis of Observational Studies. , 2016, Chest.
[28] B. Meier,et al. Impact of chronic kidney disease on left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation. , 2016, International journal of cardiology.
[29] A. Santoro,et al. Warfarin use, mortality, bleeding and stroke in haemodialysis patients with atrial fibrillation. , 2015, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[30] E. Edelman,et al. Dabigatran and Rivaroxaban Use in Atrial Fibrillation Patients on Hemodialysis , 2015, Circulation.
[31] Saibal Kar,et al. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. , 2014, JAMA.
[32] G. Lip,et al. Atrial fibrillation in CKD: balancing the risks and benefits of anticoagulation. , 2013, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[33] Gerhard Hindricks,et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association. , 2012, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[34] Jeroen J. Bax,et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. , 2012, European heart journal.
[35] C. Clase,et al. Systematic review and meta-analysis of incidence, prevalence and outcomes of atrial fibrillation in patients on dialysis. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[36] D Bergqvist,et al. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients , 2010, Journal of thrombosis and haemostasis : JTH.
[37] S. Schulman,et al. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients , 2005, Journal of thrombosis and haemostasis : JTH.